share_log

Cardiff Oncology Analyst Ratings

Benzinga Analyst Ratings ·  Sep 16, 2022 06:12
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/16/2022 738.32% HC Wainwright & Co. $22 → $14 Maintains Buy
09/13/2022 199.4% Piper Sandler $7 → $5 Maintains Overweight
08/29/2022 259.28% Baird $9 → $6 Maintains Outperform
05/09/2022 1217.37% HC Wainwright & Co. $25 → $22 Maintains Buy
02/28/2022 1397.01% HC Wainwright & Co. $26 → $25 Maintains Buy
12/08/2021 1037.72% Baird → $19 Initiates Coverage On → Outperform
08/10/2021 1456.89% HC Wainwright & Co. $25 → $26 Maintains Buy
05/10/2021 1397.01% HC Wainwright & Co. $27 → $25 Maintains Buy
10/22/2020 1516.77% HC Wainwright & Co. → $27 Initiates Coverage On → Buy
10/08/2020 1397.01% Piper Sandler → $25 Initiates Coverage On → Overweight
09/18/2020 738.32% Maxim Group $6 → $14 Maintains Buy

Cardiff Oncology Questions & Answers

What is the target price for Cardiff Oncology (CRDF)?

The latest price target for Cardiff Oncology (NASDAQ: CRDF) was reported by HC Wainwright & Co. on September 16, 2022. The analyst firm set a price target for $14.00 expecting CRDF to rise to within 12 months (a possible 738.32% upside). 6 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Cardiff Oncology (CRDF)?

The latest analyst rating for Cardiff Oncology (NASDAQ: CRDF) was provided by HC Wainwright & Co., and Cardiff Oncology maintained their buy rating.

When is the next analyst rating going to be posted or updated for Cardiff Oncology (CRDF)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cardiff Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cardiff Oncology was filed on September 16, 2022 so you should expect the next rating to be made available sometime around September 16, 2023.

Is the Analyst Rating Cardiff Oncology (CRDF) correct?

While ratings are subjective and will change, the latest Cardiff Oncology (CRDF) rating was a maintained with a price target of $22.00 to $14.00. The current price Cardiff Oncology (CRDF) is trading at is $1.67, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment